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Human prostate cancer frequently metastasizes to bone marrow. What defines the cellular and molecular predilection for
prostate cancer to metastasize to bone marrow is not well understood. CD4
+CD25
+ regulatory T (Treg) cells contribute to
self-tolerance and tumor immune pathology. We now show that functional Treg cells are increased in the bone marrow
microenvironment in prostate cancer patients with bone metastasis, and that CXCR4/CXCL12 signaling pathway con-
tributes to Treg cell bone marrow trafficking. Treg cells exhibit active cell cycling in the bone marrow, and bone marrow
dendritic cells express high levels of receptor activator of NFkB (RANK), and promote Treg cell expansion through RANK
and its ligand (RANKL) signals. Furthermore, Treg cells suppress osteoclast differentiation induced by activated T cells and
M-CSF, adoptive transferred Treg cells migrate to bone marrow, and increase bone mineral intensity in the xenograft
mouse models with human prostate cancer bone marrow inoculation. In vivo Treg cell depletion results in reduced bone
density in tumor bearing mice. The data indicates that bone marrow Treg cells may form an immunosuppressive niche
to facilitate cancer bone metastasis and contribute to bone deposition, the major bone pathology in prostate cancer
patients with bone metastasis. These findings mechanistically explain why Treg cells accumulate in the bone marrow,
and demonstrate a previously unappreciated role for Treg cells in patients with prostate cancer. Thus, targeting Treg
cells may not only improve anti-tumor immunity, but also ameliorate bone pathology in prostate cancer patients with
bone metastasis.
Introduction
Bone marrow has long been known to be a primarily hemato-
poietic organ. However, there has been a growing realization
regarding the importance of the bone marrow in immunity.
1 For
example, long-lived, antibody-secreting plasma cells reside in bone
marrow.
2 Further, a number of reports have shown that functional
memory T cells exist in bone marrow.
3,4 Bone marrow can serve as
a site for naïve tumor associated antigen (TAA)-specific T cell
priming.
3-7 Interestingly, TAA-specific T cells isolated from bone
marrow in tumor bearing mice and cancer patients are functional
in vitro and are able to prevent tumor growth upon being
transferred to another host. These observations indicate that the
TAA-specific T cells are functionally suppressed in the bone
marrow.
4-10 In line with this, we and others have previously shown
that in the homeostatic situation, mouse bone marrow harbors
high levels of functional CD4
+Foxp3
+ regulatory T (Treg) cells.
9,10
This suggests that Treg cells may form an immune suppressive
niche in bone marrow, and this niche is physiologically important
to keep potential inflammation at bay in this important and
unique hematopoietic organ. However, it is unknown if bone
marrow Treg cell compartment is altered in cancer patients with
bone metastasis, and if so, what are the underlying cellular and
molecular mechanisms?
In keeping these questions in mind, we further raise the point,
in addition to immunosuppression, do bone marrow Treg cells
affect bone pathology mediated by tumor bone metastasis in
humans? It is well known that many human cancers including
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prostate cancer frequently metastasize to the bone marrow.
However, the mechanisms that account for the cellular and
molecular predilection for tumors to metastasize to bone marrow
are not well defined. It is generally thought that tumor cells play
major roles in bone pathology induced by tumor bone metastasis.
It is also unknown whether immune cells including Treg cells
have an impact on bone immunopathology in prostate cancer
patients with bone metastasis. In order to preliminarily address
these questions, we hypothesized that tumor bone marrow
environmental cells provide cellular and molecular signals for
Treg cell accumulation, and that high levels of Treg cells
contribute to bone immunopathology in tumor bone marrow
metastasis. We tested these hypotheses in patients with prostate
cancer and in animal models. Our results demonstrate that high
levels of Treg cells accumulate in the bone marrow in prostate
cancer patients with bone metastasis, and the interaction between
dendritic cells (DCs) and Treg cells promote Treg expansion, and
in turn Treg cells suppress osteoclast differentiation and function,
contribute to bone deposition, the predominant pathology of
cancer bone metastasis.
Results
High levels of functional Treg cells in prostate cancer associated
bone marrow. Prostate cancer frequently metastasizes to bone
marrow. Recent reports suggest that bone marrow is a site for
important T cell events.
6,7,11 We previously observed high levels of
Treg cells in normal bone marrow.
9 We now examined the Treg
compartment in patients with prostate cancer. We first showed
that the fraction of Treg cells in CD4
+ T cells was significantly
higher in bone marrow in patients with prostate cancer without
bone metastasis than that in normal blood and blood from
patients with prostate cancer (n = 8, p , 0.01 for each).
Interestingly, the levels of Treg cells were significantly higher in
bone marrow from patients with prostate cancer bone marrow
metastasis (37 ± 11%, n = 6, p , 0.001) than that in the bone
marrow in prostate cancer patients without bone marrow
metastasis (18 ± 8%, n = 6) (Fig.1A and B). Thus, high levels
of Treg cells are found in prostate cancer bone marrow metastasis.
We further tested if Treg cells associated with prostate cancer
bone metastasis were functional. To this end, we employed a
Figure1. High levels of functional Treg cells in prostate cancer associated bone marrow. (A and B) High levels of CD4
+Foxp3
+ cells in bone marrow. Bone
marrow and blood single cell suspensions were made from normal age-matched male donors (n = 8) and patients with prostate cancer (PC) (n = 6).
The cells were subject to staining with anti-CD3, anti-CD4 and anti-FOXP3. Cells were analyzed with multiple color staining. The histogram showed
the percentage of FOXP3
+ cells in CD3
+CD4
+ (A). One of 6–8 donors is shown. Results are expressed as the mean values ± SD (B) *p , 0.01. PC, prostate
cancer. (C–E) Bone marrow Treg cells are functional. CD3
+CD4
+CD25
high cells were sorted with FACSAria, to high purity (. 97%), from bone marrow
in patients with prostate cancer. Autologous CD3
+CD25
- blood T cells (5   10
4/ml) were stimulated with anti-CD3 (5 mg/ml) for 3 d with or without
different numbers of Treg cells. T cell proliferation was detected by [
3H] thymidine incorporation (C) and the production of interferon-c (D) and IL-2
(E) were detected by ELISA. (n = 5; *p , 0.01). Three patients in Gleason grade 4 and 3 in grade 5, and 2 patients in stage T3a, 2 in T3b and 2 in M1.
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well-established assay that assesses the ability of Treg cells to
mediate T cell suppression.
12-15 We showed that bone marrow
Treg cells from patients with prostate cancer inhibited T cell
proliferation in a dose dependent manner (Fig.1C). Bone marrow
Treg cells also suppressed IFNc and IL-2 production of T cells
(Fig.1D and E) (n = 5, *p , 0.01). Thus, Treg cells in bone
marrow in patients with prostate cancer are functional regulatory
T cells.
Treg cells migrate toward bone marrow via CXCR4/CXCL12
signaling pathway. We next examined why Treg cells were
accumulated in bone marrow associated with prostate cancer. The
first possibility is that Treg cells efficiently traffic to bone marrow
in patients with prostate cancer. We showed that Treg cells
isolated from bone marrow associated with prostate cancer
migrated toward human bone marrow fluid (Fig.2A), and anti-
human CXCR4 significantly decreased this migration (Fig.2A).
Further, we showed that human bone marrow produced a high
level of CXCL12, the ligand for CXCR4. The levels of CXCL12
were higher in prostate cancer patients with bone marrow
metastasis than normal donors (Fig.2B). In further support,
variable expression levels of several common chemokine receptors
including CCR2, CCR4, CCR5, CCR7 and CXCR2 were
detected in the bone marrow Treg cells, however, these Treg cells
expressed high levels of CXCR4 (Fig.2C). Therefore, the data
suggests that Treg cells migrate to prostate cancer associated bone
marrow by CXCR4/CXCL12 signaling pathway.
Treg cells actively expand in tumor associated bone marrow.
After examining the possibility of Treg cell bone marrow traffick-
ing, we further analyzed whether Treg cells were actively
expanded in the tumor associated bone marrow in patients with
prostate cancer. We showed that normal bone marrow Treg cells
contained up to 7% Ki67 expressing cells whereas there were 1%
Ki67
+ Treg cells in peripheral blood. Interestingly, there were
32% Ki67
+ bone marrow Treg cells in patients with prostate
cancers (Fig.3A and B). In accord with this, the expression of
multiple cyclin genes was higher in bone marrow Treg cells than
conventional T cells (Fig.3C). On the contrary, the expression of
multiple CDK inhibitors was lower in bone marrow Treg cells
than conventional T cells (Fig.3D). The data suggests that Treg
cells in the tumor associated bone marrow selectively experience a
pathological expansion.
RANK
+ DCs induce Treg cell expansion in tumor associated
bone marrow. We further investigated the cellular mechanism
by which Treg cells were expanding in the tumor associated
bone marrow. We hypothesized that tumor associated DCs
might induce Treg cells expansion. We sorted blood Treg cells
Figure2. Treg migrate toward bone marrow through CXCR4/CXCL12. (A) Bone marrow Treg were subject to migrating with normal human bone marrow
fluid or human bone marrow fluid from patients with bone marrow metastasis. Anti-CXCR4 and isotype were added in the migration assay (n = 6; *p , 0.01;
compared with medium or anti-CXCR4). (B) Human bone marrow expressed high level of CXCL12. CXCL12 was measured by ELISA in bone marrow fluid
and blood from normal donors (n = 6) and patients with prostate cancer (n = 5). Results are expressed as mean ± SD *p , 0.01. (C) Bone marrow Treg
cells expressed high levels of CXCR4. Bone marrow cells were stained with anti-CCR2, CCR4, CCR5, CCR7, CXCR2 and CXCR4 and Treg cell markers, and
analyzed with LSR II. The chemokine receptor expression was determined by gating on CD3
+CD4
+Foxp3
+ cells. One of 6 representatives is shown.
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and cocultured with DCs from different sources. We showed that
regardless of their source, DCs efficiently induced Treg cell
expansion. However, tumor associated bone marrow DCs were
superior to inducing Treg cell expansion as compared with DCs
from normal bone marrow and blood (Fig.4A). Interestingly,
tumor bone marrow-associated DCs highly expressed RANK.
DCs from normal blood or bone marrow without tumor in the
bone marrow expressed little RANK (Fig.4B). These DCs
expressed similar levels of CD40 (Fig.4B). To study the effects of
RANK
+ DCs on Treg cell expansion, we sorted RANK
+ and
RANK
- DCs from tumor associated bone marrow, and cultured
with Treg cells. We observed that RANK
+ and RANK
- DCs
induced Treg cell expansion, however, RANK
+ DCs were
more efficient than RANK
- DCs to induce Treg cell expansion
(Fig.4C). Furthermore, blocking RANK/RANKL signaling
pathway with recombinant osteoprotegerin (OPG) ablated the
stimulatory effects of RANK
+ DCs on Treg cell expansion
(Fig.4C). These observations suggest that RANK
+ DCs
may be responsible for Treg cell expansion in patients with
prostate cancer.
Treg cells suppress osteoclast differentiation and function. In
addition to immune suppression (Fig.1), we hypothesized that
high levels of Treg cells in the tumor associated bone marrow
might affect bone pathology in prostate cancer. To test this, we
sorted Treg cells and tested their potential roles in osteoclast
differentiation induced by recombinant RANKL and M-CSF. As
expected, Treg cells reduced the numbers of tartrate-resistant acid
phosphatase (TRAP)-positive cells induced by RANKL (Fig.5A
and B) and M-CSF in a dose dependent manner (Fig.5C). As
activated CD8
+ T cells were observed in bone marrow in patients
with cancer,
3-6 we further tested if Treg cells affected T cell-
mediated osteoclast differentiation. We observed that TRAP
+ cells
were increased in CD8
+ T cell coculture as compared with no
T cells. Treg cells reduced the numbers of TRAP
+ cells induced by
CD8
+ T cells in a dose dependent manner (Fig.5D). The data
indicates that Treg cells suppress osteoclast differentiation.
Figure3. Treg cells actively expand in tumor associated bone marrow. Blood and bone marrow were immediately stained with anti-CD3, anti-CD4, anti-
FOXP3 and anti-Ki67 and were analyzed with LSR II. (A) Representative dot plots showed Ki67 expression in normal vs. tumor bone marrow Foxp3
+ Treg
cells. (B) Results are expressed as the percentage of Ki67 expressing cells in CD4
+FOXP3
+CD3
+ cells (Treg cells) (mean ± SEM) (n = 6–8, *, Tumor bone
marrow compared with normal bone marrow, and other compartments, p , 0.001). (C and D) Bone marrow Treg cells expressed different levels of cell
cycling genes. Expression of multiple cyclin genes (C) and CDK inhibitors (D) was quantified in bone Treg cells and conventional T cells by real-time PCR.
Results are expressed as mean ± SD n = 5, *p , 0.01.
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Treg cells increase bone formation in tumor bearing mice. We
tested the effects of Treg cells in vivo on bone pathology in our
established human prostate cancer chimeric model. Human
prostate cancer cells PC-3 were inoculated into tibia of NOD.
SCID mice by intratibial injection.
16-20 Tumor bone establish-
ment was examined with both in vivo bioluminescence and
radiographic imaging. Activated Treg cells were transfused into
the mice by intravenous injection seven days after the establish-
ment of bone metastasis. We showed that Treg cells increased
bone mineral density (BMD) (Fig.6A), bone mineral content
(BMC) (Fig.6B) and ameliorated bone destruction of tibial
trabeculae (Fig.6C) compared with control.
We further investigated the role of Treg cells in bone pathology
in immune competent mice. To this end, RM1 tumor was
initially established in the Bacterial artificial chromosome (BAC)-
transgenic depletion of regulatory T cell (DEREG) mouse
model.
21 Then, we injected diphtheria toxin to deplete Treg
cells. Treg cells were efficiently depleted on day two, and were
gradually recovered on day ten in different organs (Fig.S1).
Interestingly, the levels of bone marrow Treg cells remained low
on day 17 (Fig.S1). We measured BMD and BMC on day 15.
We observed that Treg cell depletion resulted in partial but
significant reduction of BMD (Fig.6D) and BMC (Fig.6E).
Altogether, the data indicates that Treg cells may suppress
osteoclast differentiation or function in vivo in immune
competent mice.
Discussion
In this report, we observed active Treg cell recruitment and
expansion in bone marrow of prostate cancer patients with bone
metastasis. Furthermore, the bone marrow Treg cells tilt the
balance between osteoclast and osteoblast activity, which poten-
tially contributes to osteoblastic bone lesions that characterize
prostate cancer. Finally, we have defined that CXCR4/CXCL12
and RANK/RANKL are crucial molecular signaling pathways for
Treg cell bone marrow trafficking and expansion, respectively.
Several immune suppressive elements including Treg cells
form immunosuppressive networks in the tumor microenviron-
ment.
22-26 We have previously demonstrated that under home-
ostatic situation, the levels of Treg cells in bone marrow are
relatively high in healthy human beings as compared with
peripheral blood and lymph nodes.
9 This observation was
confirmed in a FOXP3 bicistronic reporter knock-in mouse
model.
10 However, it was unknown if and how bone marrow Treg
cells are altered in pathological scenarios. We have now observed
higher levels of Treg cells in bone marrow in prostate cancer
patients with bone metastasis as compared with healthy donors
and patients without bone metastasis. Interestingly, prostate
cancer cells and bone marrow stromal cells express high levels of
CXCL12
27-29 and bone marrow Treg cells express CXCR4, and
efficiently migrate toward bone marrow through CXCR4/
CXCL12 signaling pathway.
9 That activated, but not resting
Figure4. RANK
+ DCs induce Treg cell expansion in tumor associated bone marrow. (A) Prostate cancer associated bone marrow DCs stimulated Treg cell
expansion. Bone marrow lin
-CD11c
+ DCs were sorted from human bone marrow, and cultured with blood Treg cells for 4 d as described. The resultant
cells were stained with anti-Foxp3. Results are expressed the absolute numbers of Treg cells ± SD n = 5, p , 0.01. (B) Prostate cancer BM DCs expressed
RANK. BM cells were stained for DC phenotype and RANK. Results are expressed the percent of RANK
+ cells in lin
-CD11c
+ DCs. One of 5 is shown.
(C) Prostate cancer BM DCs mediated Treg cell expansion through RANK. RANK
+ and RANK
- DCs were sorted and cultured with Treg cells as described
(A) in the absence or presence of OPG. Cells were collected for detecting Foxp3 with LSR by gating on CD3
+CD4
+ viable cells. Results are expressed as
the absolute numbers of Foxp3
+ cells ± SD n = 5, *p , 0.01.
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Treg cells express high amount of CXCR4, indicates that Treg
cells may be activated in the tumor and efficiently traffic to bone
marrow, where they exert immune suppression and that
immunologically facilitates tumor bone marrow metastasis.
Treg cells in bone marrow with prostate cancer metastasis
express high levels of Ki67. This indicates that tumor-associated
bone marrow is an organ where Treg cells actively expand.
Although active bone marrow trafficking may be one of the
reasons that Treg cells accumulate in bone marrow of patients
with prostate cancer, extensive Treg cell expansion is an additional
cause. We have determined that CXCL12/CXCR4 signaling
pathway is responsible for Treg bone marrow migration and
we have further explored cellular and molecular mechanisms
governing Treg cell expansion in bone marrow. We demonstrated
that tumor associated DCs, but not the control counterparts,
induce Treg cell expansion. Interestingly, DCs from bone marrow
with metastatic tumor selectively and highly expressed RANK and
blockade of RANK/RANKL signaling pathway disables the effects
of DC-mediated Treg cell expansion. Although IL-2 induces Treg
cell expansion
30-33 and TGF  promotes Treg cell conversion from
naïve T cells,
34 our data indicates that the interaction between
DCs and Treg cells through RANK/RANKL signaling pathway is
an additional signal crucial for Treg cell expansion in specific
pathological environments including prostate cancer. In support
of our human studies in cancer, it has been reported that RANKL
and RANK signals are implicated in Treg cell expansion in mouse
models with diabetes
35 and UV-induced immune suppression.
36
Taken together, to ensure Treg cell bone marrow accumulation
and function, bone marrow environmental cells, such as RANK
+
DCs provide specific molecular signals for Treg cell expansion and
in turn Treg cells mediate immune suppression, and contribute to
tumor bone metastasis. Our studies focused on prostate cancer,
however, it would also be interesting to examine the relationship
between tumor bone metastasis and Treg cells in other human
cancer settings including breast cancer.
The formation and remodeling of bone is a complex
physiological process relying on a strict balance between the
resorptive activity of osteoclasts and the synthesis of bone matrix
by osteoblasts. RANKL/RANK is an important molecular signal
pathway controlling bone remodeling and is essential for the
development and activation of bone-resorbing osteoclasts. Normal
bone homeostasis is achieved by a balance between the bone
resorbing effects of RANKL and its natural decoy receptor
OPG.
37 Inhibition of RANKL activity with either OPG or a
Figure5. Treg cells suppress osteoclast differentiation in vitro. (A–B) Treg cells suppressed osteoclast differentiation mediated by RANKL. Mouse bone
marrow cells (BMCs) were cultured as described with RANKL in the absence or presence of Treg cells. The cultured cells were subject to TRAP staining.
TRAP-positive multinucleated (. 3 nuclei) cells were counted. (A) Results are reported as the number of osteoclast (OC)-like cells per coverslip ± SD n = 5,
*p , 0.01. (B) Representative images showed osteoclast (OC)-like cells. (C and D) Treg cells suppressed osteoclast differentiation mediated by M-CSF and
CD8
+ T cells. Mouse bone marrow cells were cultured as described with M-CSF (C) or activated CD8
+ T cells (D) in the presence of different concentrations
of Treg cells. Results are reported as the number of osteoclast (OC)-like cells per coverslip ± SD n = 6, *p , 0.01.
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soluble RANK can inhibit prostate cancer growth including in
bone.
19 RANKL antibody (Denosumb) was recently approved to
inhibit skeletal-related events in prostate cancer.
38,39 The function
of RANKL/RANK interactions outside the bone cells and tumor
cells is not well defined in the context of prostate cancer. Activated
T cells produce RANKL and can directly trigger osteoclasto-
genesis in vitro through RANK, while systemic activation of
T cells in vivo results in a RANKL-mediated increase in
osteoclastogenesis and bone loss.
40 Although RANKL/RANK
pathway is involved in Treg cell expansion in the cancer metastasis
to bone marrow, we show that Treg cells inhibit osteoclast
differentiation mediated by activated T cells or M-CSF and
RANKL, and directly increase bone mineral density in prostate
cancer. This is consistent with the observation in mouse
autoimmune disease models.
41,42 It remains to be defined how
Treg cells do so in vivo in patients with prostate cancer. It is
generally thought that prostate cancer cells play a major role in
bone pathology in prostate cancer patients with bone metastasis.
Our results indicate that Treg cells directly and indirectly suppress
osteoclast differentiation and function, contribute to bone
deposition, the important pathology of cancer bone metastasis.
Given the high amount of Treg cells in prostate cancer associated
bone marrow, our data provides important novel insight into
osteoimmunology. As CXCR4/CXCL12 and RANKL/RANK
signaling pathways are involved in immune and tumor pathology
in prostate cancer bone metastasis, it is suggested that the
combinatorial blockade of these two signaling pathways would
be a valid option to treat patients with prostate cancer, and to
ameliorate prostate cancer bone metastasis.
In summary, bone marrow in patients with prostate cancer
harbors a high prevalence of functional Treg cells due to active
recruitment and expansion. Treg cells interact with bone
environmental cells, and this interaction provides an immune
and biological environment that could favor tumor retention,
growth and invasion. Thus, bone marrow Treg cells contribute
to tumor bone metastatic pathology. Targeting Treg cell bone
marrow recruitment and expansion may be therapeutically
meaningful to treat cancer patients with bone metastasis.
Patients and Materials and Methods
Human subjects. Human bone marrow aspiration was obtained
from the posterior iliac crest based on standard clinical procedure
(http://www.mayoclinic.com/health/bone-marrow), and was
placed in an anticoagulant tube. Certain amounts of bone
marrow aspirates were used to make the appropriate slides for
Figure6. Treg cells suppress osteoclast differentiation and function in vivo. (A–C) Human Treg cells suppressed osteoclast differentiation. Prostate cancer
bone metastasis was established in NOD.SCID mice with PC-3 intratibial injection. On day 7 after tumor inoculation, mice were intravenously transfused
with activated Treg cells. On day 25, BMD (A) and BMC (B) of tibial trabeculae were measured. Representative radiographic images showed the bone
destruction of tibial trabeculae (C) on day 25. Results are expressed as mean ± SD n = 6/group, *p , 0.05. (D and E) Mouse Treg cells suppressed osteoclast
differentiation. RM1 tumor bone metastasis was established in DEREG mice with tumor intratibial injection. Treg cells were depleted with DT injection. On
day 15, BMD (D) and BMC (E) of tibial trabeculae were measured. Results are expressed as mean ± SD n = 5/group, *p , 0.05. DT, diphtheria toxin.
158 OncoImmunology Volume 1 Issue 2© 2012 Landes Bioscience.
Do not distribute.
pathology. Most of the bone marrow aspirates were frozen in -80°C
for further functional experiments as we described previously.
9
The cellular particles were diluted into single cell suspension with
flow cytometry buffer for phenotyping and functional experiments
as we described.
9 Peripheral blood was from commercial Buffy coat
cells. Donors gave written, informed consent. The study was
approved by the Local Institutional Review Boards.
Mice. Bacterial artificial chromosome (BAC)-transgenic deple-
tion of regulatory T cell (DEREG) mice on the C57BL/6
background were described previously
21 and kept in specific
pathogen-free conditions. NOD.SCID mice and wild type
C57BL/6 mice were purchased from The Jackson Laboratory.
Animal protocol was approved by the Unit for Laboratory Animal
Medicine of University of Michigan and was conducted in
accordance with the National Institutes of Health’s Guide for the
Care and Use of Laboratory Animals.
Cell lines. Human prostate cancer cell line PC-3 and murine
prostate cancer cell line RM1
43 were used in this study. PC-3 cells
were stably transfected with a lux reporter vector which contains a
constitutively active promoter driving luciferase expression.
19,44
PC-3 and RM1 cells were cultured in vitro in RPMI 1640 supple-
mented with 10% fetal bovine serum (FBS), 100U/ml penicillin,
100mg/ml streptomycin and regularly passaged by trypsinization.
Flow cytometry analysis. T cells were first stained extracellularly
with specific antibodies against human CD3 and CD4 (BD
Biosciences), then were fixed and permeabilized with Perm/Fix
solution (eBioscience) and finally were stained intracellularly with
anti-Ki67, anti-IL-2, anti-IFNc (BD Biosciences) and anti-Foxp3
antibodies (eBioscience). Human dendritic cells were stained with
lineage markers, anti-CD11c and anti-RANK antibodies (R&D
System). Samples were acquired on a LSR II (BD Biosciences) and
data were analyzed with DIVA software (BD Biosciences).
T cell proliferation and cytokine expression. Primary T cells
were stimulated with 2.5 mg/mL anti-CD3 and 1.25 mg/mL anti-
CD28 monoclonal antibody (BD Biosciences) for 4 d in the
presence of different concentrations of Treg cells. T cell prolifera-
tion was defined by thymidine incorporation on day 3. T cell
cytokines were determined by LSR II.
DC and Treg cell coculture. Lin
-CD11c
+ DCs were cultured
with sorted CD4
+CD25
high T cells
45,46 in the presence of
2.5 mg/mL anti-CD3 (BD Biosciences) and 5 ng/ml IL-2
(R&D System) for 4 d. T cell phenotype was determined by
LSR II. The absolute numbers of Foxp3
+ cells were recorded.
Migration assay. Migration was assessed as we described using
human CD4
+CD25
high Treg cells (5–20   10
4).
14,45 Treg cells
were induced to migrate with 100 ng/ml recombinant human
CXCL12 (R&D System), or human bone marrow fluid. Treg
cells were incubated with 500 ng/ml mouse anti-human-CXCR4
(R&D System) for 2 h as indicated. Identity of migrating Treg
cells was further confirmed by flow cytometry analysis for CD3,
CD4 and Foxp3 expression. Migration was expressed as a
percentage of migrated cells after subtracting the spontaneous
migration (Migration index).
14,45
Quantitative real-time PCR and ELISA. General quantitative
real-time PCR was done as described.
45,47 The expression of
detected genes was calculated as the relative expression to
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The infor-
mation of the primers was listed in Table S1.C X C L 1 2p r o t e i ni n
the bone marrow fluids was detected by ELISA (R&D System).
Osteoclast differentiation assay. Osteoclast differentiation
assay was performed as we described.
19 Briefly, bone marrow
cells (BMCs) were obtained from C57BL/6 mice by flushing the
medullary cavities of tibia and femur of the bilateral hind limbs
with Dulbecco modified Eagle’s medium (DMEM). These cells
were cultured with 10 ng/ml M-CSF (R&D System), 50 ng/ml
recombinant soluble RANKL (PeproTech) for 3 d in the presence
of 20 ng/ml recombinant mouse IL-2 (R&D System). Different
concentrations of CD8
+ T cells or Treg cells (1   10
6/ml) were
pre-activated with 2.5 mg/ml anti-CD3 and 1.25 mg/ml anti-
CD28 monoclonal mouse antibodies (BD Biosciences) for 12 h as
we described,
48 and then added into the BMCs culture for 3 d.
The resultant cells were evaluated in quadruplicates. Osteoclast-
like cells were identified as tartrate-resistant acid phosphatase
(TRAP)-positive multinucleated (. 3 nuclei) cells with leukocyte
acid phosphatase kit (Sigma) as described.
19,49
In vivo bioluminescent imaging and radiography. In vivo
Bioluminescent Imaging was performed with an IVIS Spectrum
imaging system (Xenogen Corporation, Alameda, CA) and high-
resolution radiographic images of mice were obtained using a
Faxitron laboratory radiography system LX-60 (Faxitron X-ray
Corporation, Wheeling, IL) at 30 KVp for 10 sec.
19,44,49
Human chimeric model. The stable transfectant PC-3 cells
used in in vivo study were first tested in vitro by adding 20 ml
luciferin (40 mg/ml) into the 96-well plate. These PC-3 cells
(5   10
5) were intratibially injected into 4–5-week-old, male
NOD.SCID mice.
16-20 Tumor bone establishment was examined
with both the in vivo bioluminescence intensity on a cryogenically
cooled imaging system (Xenogen Corporation, Alameda, CA)
coupled to a data acquisition computer and radiographic imaging.
Once tumors were well established in the bone, activated Treg
cells (6   10
6)
45,47 were injected intravenously into mice on day 7
after human prostate cancer inoculation. On day 25, all the mice
were sacrificed and tibiae were harvested and fixed in 10%
formalin. BMD and BMC of tibial trabeculae were measured on
an Eclipse Peripheral Dexa Scanner (Norland Medical Systems).
44
In vivo treg depletion. DEREG mice were injected intratibially
with RM1 cells into the right tibia as described.
43 Mice were given
1mg diphtheria toxin(DT)(Merck) dilutedin100mlendotoxin-free
PBS or 100 ml endotoxin-free PBS alone by intraperitoneal injection
on day 1, 3 and 5. DT treatment efficiently reduced Treg cells in
bone marrow (Fig.S1).
50 All the mice were sacrificed on day 15 and
tibiae were fixed in 10% formalin. BMD and BMC were measured.
Acknowledgments
This research is supported in part by research grants from the
National Institutes of Health CA133620 (W.Z.), CA93900 (E.T.
K.) and the NIH through the University of Michigan’s Cancer
Center Support Grant (P30CA46592). We thank to Deborah
Postiff in the tissue procurement core for her technical assistance.
Disclosure opf Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
www.landesbioscience.com OncoImmunology 159© 2012 Landes Bioscience.
Do not distribute.
Note
Supplementary materials can be found at:
www.landesbioscience.com/journals/oncoimmunology/article/18480/
References
1. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al.
Bone marrow and the control of immunity. Cell Mol
Immunol 2011. In press; PMID:22020068; http://dx.
doi.org/10.1038/cmi.2011.47
2. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral
immunity due to long-lived plasma cells. Immunity
1998; 8:363-72; PMID:9529153; http://dx.doi.org/10.
1016/S1074-7613(00)80541-5
3. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone
marrow is a preferred site for homeostatic proliferation
of memory CD8 T cells. J Immunol 2005; 174:1269-
73; PMID:15661882
4. Mazo IB, Honczarenko M, Leung H, Cavanagh LL,
Bonasio R, Weninger W, et al. Bone marrow is a major
reservoir and site of recruitment for central memory
CD8+ T cells. Immunity 2005; 22:259-70; PMID:
15723813; http://dx.doi.org/10.1016/j.immuni.2005.
01.008
5. Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone
marrow can function as a lymphoid organ during a
primary immune response under conditions of dis-
rupted lymphocyte trafficking. J Immunol 1997; 158:
3716-20; PMID:9103435
6. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer
A, Hommel M, et al. Bone marrow as a priming site
for T-cell responses to blood-borne antigen. Nat Med
2003; 9:1151-7; PMID:12910264; http://dx.doi.org/
10.1038/nm914
7. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert
G, Diel IJ, et al. Therapy of human tumors in NOD/
SCID mice with patient-derived reactivated memory
T cells from bone marrow. Nat Med 2001; 7:452-8;
PMID:11283672; http://dx.doi.org/10.1038/86523
8. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer
EF, Bastert G, et al. Enrichment of memory T cells
and other profound immunological changes in the
bone marrow from untreated breast cancer patients.
Int J Cancer 2001; 92:96-105; PMID:11279612;
http://dx.doi.org/10.1002/1097-0215(200102)9999:
9999,::AID-IJC1152.3.0.CO;2-Q
9. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-
Hogan M, Mottram P, et al. Bone marrow is a reservoir
for CD4+CD25+ regulatory T cells that traffic through
CXCL12/CXCR4 signals. Cancer Res 2004; 64:8451-5;
PMID:15548717; http://dx.doi.org/10.1158/0008-5472.
CAN-04-1987
10. Wan YY, Flavell RA. Identifying Foxp3-expressing
suppressor T cells with a bicistronic reporter. Proc Natl
Acad Sci USA 2005; 102:5126-31; PMID:15795373;
http://dx.doi.org/10.1073/pnas.0501701102
11. Dhodapkar MV, Krasovsky J, Osman K, Geller MD.
Vigorous Premalignancy-specific Effector T Cell Res-
ponse in the Bone Marrow of Patients with Mono-
clonal Gammopathy. J Exp Med 2003;198:1753-7.
12. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM.
CD4+CD25+ T cells inhibit both the induction and
effector function of autoreactive T cells and represent a
unique lineage of immunoregulatory cells. J Immunol
1998; 160:1212-8; PMID:9570536
13. Thornton AM, Shevach EM. Suppressor effector func-
tion of CD4+CD25+ immunoregulatory T cells is
antigen nonspecific. J Immunol 2000; 164:183-90;
PMID:10605010
14. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J,
Nome F, Isaeva T, et al. Stromal-derived factor-1 in
human tumors recruits and alters the function of
plasmacytoid precursor dendritic cells. Nat Med 2001;
7:1339-46; PMID:11726975; http://dx.doi.org/10.
1038/nm1201-1339
15. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P,
Mottram P, et al. Blockade of B7-H1 improves myeloid
dendritic cell-mediated antitumor immunity. Nat Med
2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.
1038/nm863
16. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen
MJ, Pienta KJ, et al. Bone turnover mediates
preferential localization of prostate cancer in the
skeleton. Endocrinology 2005; 146:1727-36; PMID:
15637291; http://dx.doi.org/10.1210/en.2004-1211
17. Cooper CR, Chay CH, Gendernalik JD, Lee HL,
Bhatia J, Taichman RS, et al. Stromal factors involved
in prostate carcinoma metastasis to bone. Cancer 2003;
97:739-47; PMID:12548571; http://dx.doi.org/10.
1002/cncr.11181
18. Park BK, Zhang H, Zeng Q, Dai J, Keller ET,
Giordano T, et al. NF-kappaB in breast cancer cells
promotes osteolytic bone metastasis by inducing osteo-
clastogenesis via GM-CSF. Nat Med 2007; 13:62-9;
PMID:17159986; http://dx.doi.org/10.1038/nm1519
19. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C,
et al. Osteoprotegerin inhibits prostate cancer-induced
osteoclastogenesis and prevents prostate tumor growth
in the bone. J Clin Invest 2001; 107:1235-44; PMID:
11375413; http://dx.doi.org/10.1172/JCI11685
20. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z,
et al. Osteoblasts induce prostate cancer proliferation and
PSA expression through interleukin-6-mediated activa-
tion of the androgen receptor. Clin Exp Metastasis 2004;
21:399-408; PMID:15672864; http://dx.doi.org/10.
1007/s10585-005-0056-6
21. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason
J, Eberl G, et al. Selective depletion of Foxp3+
regulatory T cells induces a scurfy-like disease. J Exp
Med 2007; 204:57-63; PMID:17200412; http://dx.
doi.org/10.1084/jem.20061852
22. Spiotto MT, Yu P, Rowley DA, Nishimura MI,
Meredith SC, Gajewski TF, et al. Increasing tumor
antigen expression overcomes “ignorance” to solid
tumors via crosspresentation by bone marrow-derived
stromal cells. Immunity 2002; 17:737-47; PMID:
12479820; http://dx.doi.org/10.1016/S1074-7613(02)
00480-6
23. Schreiber H, Wu TH, Nachman J, Kast WM.
Immunodominance and tumor escape. Semin Cancer
Biol 2002; 12:25-31; PMID:11926408; http://dx.doi.
org/10.1006/scbi.2001.0401
24. Zou W. Immunosuppressive networks in the tumour
environment and their therapeutic relevance. Nat Rev
Cancer 2005; 5:263-74; PMID:15776005; http://dx.
doi.org/10.1038/nrc1586
25. Zou W. Regulatory T cells, tumour immunity and
immunotherapy. Nat Rev Immunol 2006; 6:295-307;
PMID:16557261; http://dx.doi.org/10.1038/nri1806
26. Zitvogel L, Tesniere A, Kroemer G. Cancer despite
immunosurveillance: immunoselection and immuno-
subversion. Nat Rev Immunol 2006; 6:715-27;
PMID:16977338; http://dx.doi.org/10.1038/nri1936
27. Taichman RS, Cooper C, Keller ET, Pienta KJ,
Taichman NS, McCauley LK. Use of the stromal
cell-derived factor-1/CXCR4 pathway in prostate
cancer metastasis to bone. Cancer Res 2002; 62:
1832-7; PMID:11912162
28. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K,
et al. Skeletal localization and neutralization of the
SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer
metastasis and growth in osseous sites in vivo. J Bone
Miner Res 2005; 20:318-29; PMID:15647826; http://
dx.doi.org/10.1359/JBMR.041109
29. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A,
Habler L, et al. G-CSF induces stem cell mobilization
by decreasing bone marrow SDF-1 and up-regulating
CXCR4. Nat Immunol 2002; 3:687-94; PMID:
12068293; http://dx.doi.org/10.1038/ni813
30. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N,
Lafaille JJ. Interleukin 2 signaling is required for
CD4(+) regulatory T cell function. J Exp Med 2002;
196:851-7; PMID:12235217; http://dx.doi.org/10.
1084/jem.20020190
31. Malek TR, Bayer AL. Tolerance, not immunity,
crucially depends on IL-2. Nat Rev Immunol 2004;
4:665-74; PMID:15343366; http://dx.doi.org/10.
1038/nri1435
32. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W,
Banerjee M, et al. Interleukin-2 Administration Alters
the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking
in Patients with Ovarian Carcinoma. Cancer Res 2007;
67:7487-94; PMID:17671219; http://dx.doi.org/10.
1158/0008-5472.CAN-07-0565
33. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W,
Keller ET, et al. Cutting Edge: Opposite Effects of IL-1
and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1
Subverts IL-2-Mediated Suppression. J Immunol 2007;
179:1423-6; PMID:17641006
34. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N,
et al. Conversion of peripheral CD4+CD25- naive
T cells to CD4+CD25+ regulatory T cells by TGF-beta
induction of transcription factor Foxp3. J Exp Med
2003; 198:1875-86; PMID:14676299; http://dx.doi.
org/10.1084/jem.20030152
35. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-
derived CD4(+)CD25(+) Treg cells: highly potent
regulators of diabetes that require TRANCE-RANK
signals. Immunity 2002; 16:183-91; PMID:11869680;
http://dx.doi.org/10.1016/S1074-7613(02)00279-0
36. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe
S, et al. Epidermal RANKL controls regulatory T-cell
numbers via activation of dendritic cells. Nat Med
2006; 12:1372-9; PMID:17143276; http://dx.doi.org/
10.1038/nm1518
37. WalshMC,KimN,KadonoY,RhoJ,Lee SY,LorenzoJ,
et al. Osteoimmunology: interplay between the immune
system and bone metabolism. Annu Rev Immunol 2006;
24:33-63; PMID:16551243; http://dx.doi.org/10.1146/
annurev.immunol.24.021605.090646
38. Cummings SR, San Martin J, McClung MR, Siris ES,
Eastell R, Reid IR, et al. Denosumab for prevention of
fractures in postmenopausal women with osteoporosis.
N Engl J Med 2009; 361:756-65; PMID:19671655;
http://dx.doi.org/10.1056/NEJMoa0809493
39. McClung MR, Lewiecki EM, Cohen SB, Bolognese
MA, Woodson GC, Moffett AH, et al. Denosumab in
postmenopausal women with low bone mineral density.
N Engl J Med 2006; 354:821-31; PMID:16495394;
http://dx.doi.org/10.1056/NEJMoa044459
40. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony
S, et al. Activated T cells regulate bone loss and joint
destruction in adjuvant arthritis through osteo-
protegerin ligand. Nature 1999; 402:304-9; PMID:
10580503; http://dx.doi.org/10.1038/46303
41. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E,
Skapenko A, et al. Treg cells suppress osteoclast forma-
tion: a new link between the immune system and bone.
Arthritis Rheum 2007; 56:4104-12; PMID:18050211;
http://dx.doi.org/10.1002/art.23138
160 OncoImmunology Volume 1 Issue 2© 2012 Landes Bioscience.
Do not distribute.
42. Zaiss MM, Frey B, Hess A, Zwerina J, Luther J,
Nimmerjahn F, et al. Regulatory T cells protect from
local and systemic bone destruction in arthritis. J
Immunol 2010; 184:7238-46; PMID:20483756;
http://dx.doi.org/10.4049/jimmunol.0903841
43. McCabe NP, Madajka M, Vasanji A, Byzova TV.
Intraosseous injection of RM1 murine prostate cancer
cells promotes rapid osteolysis and periosteal bone
deposition. Clin Exp Metastasis 2008; 25:581-90;
PMID:18506587; http://dx.doi.org/10.1007/s10585-
008-9175-1
44. DaiJ,LuY,YuC,KellerJM,MizokamiA,ZhangJ,etal.
Reversal of chemotherapy-induced leukopenia using
granulocyte macrophage colony-stimulating factor pro-
motes bone metastasis that can be blocked with osteoclast
inhibitors. Cancer Res 2010; 70:5014-23; PMID:
20501834; http://dx.doi.org/10.1158/0008-5472.CAN-
10-0100
45. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P,
Mottram P, et al. Specific recruitment of regulatory
T cells in ovarian carcinoma fosters immune privilege and
predicts reduced survival. Nat Med 2004; 10:942-9;
PMID:15322536; http://dx.doi.org/10.1038/nm1093
46. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W,
et al. FOXP3 defines regulatory T cells in human tumor
and autoimmune disease. Cancer Res 2009; 69:3995-
4000; PMID:19383912; http://dx.doi.org/10.1158/
0008-5472.CAN-08-3804
47. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S,
Mottram P, et al. B7-H4 expression identifies a novel
suppressive macrophage population in human ovarian
carcinoma. J Exp Med 2006; 203:871-81; PMID:
16606666; http://dx.doi.org/10.1084/jem.20050930
48. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H,
et al. Cutting Edge: Induction of B7-H4 on APCs
through IL-10: novel suppressive mode for regulatory
T cells. J Immunol 2006; 177:40-4; PMID:16785496
49. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller
GA, et al. Development of anti-p185HER2 immuno-
liposomes for cancer therapy. Proc Natl Acad Sci USA
1995; 92:1327-31; PMID:7877976; http://dx.doi.org/
10.1073/pnas.92.5.1327
50. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng
MW, Ngiow SF, et al. Selective depletion of Foxp3+
regulatory T cells improves effective therapeutic
vaccination against established melanoma. Cancer Res
2010; 70:7788-99; PMID:20924102; http://dx.doi.
org/10.1158/0008-5472.CAN-10-1736
www.landesbioscience.com OncoImmunology 161